Overview
Acute sensory ataxic neuropathy (ASAN) is a rare acquired peripheral neuropathy characterized by the rapid onset of sensory ataxia — a loss of coordination caused by impaired proprioception (the body's sense of position and movement) rather than cerebellar dysfunction. It is classified within the spectrum of acute inflammatory demyelinating or axonal neuropathies and shares features with Guillain-Barré syndrome (GBS), specifically resembling an acute sensory variant. The condition predominantly affects the peripheral nervous system, targeting large-diameter sensory nerve fibers responsible for proprioception and vibration sense. Patients typically present with an acute or subacute onset of unsteadiness, difficulty walking (sensory ataxia), numbness, tingling, and loss of deep tendon reflexes (areflexia). Limb weakness is absent or minimal, distinguishing ASAN from classic motor-predominant forms of GBS. Patients may have difficulty with fine motor tasks due to impaired sensory feedback. Nerve conduction studies typically show abnormalities in sensory nerve action potentials, while motor conduction may be relatively preserved. The condition is thought to have an immune-mediated pathogenesis, and some cases are preceded by an infectious illness. Treatment is largely supportive and based on approaches used for Guillain-Barré syndrome, including intravenous immunoglobulin (IVIg) and plasmapheresis (plasma exchange), although evidence for efficacy in this specific variant is limited and largely based on case reports and small series. Physical rehabilitation focusing on balance and gait training is an important component of management. The prognosis is variable; some patients recover substantially, while others may have persistent sensory deficits and ataxia. Given its rarity, there are no large-scale clinical trials specifically addressing ASAN, and management decisions are often individualized.
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
5 eventsSeung-Jung Park
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Acute sensory ataxic neuropathy.
5 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for Acute sensory ataxic neuropathy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Acute sensory ataxic neuropathy.
Community
No community posts yet. Be the first to share your experience with Acute sensory ataxic neuropathy.
Start the conversation →Latest news about Acute sensory ataxic neuropathy
Disease timeline:
New recruiting trial: Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)
A new clinical trial is recruiting patients for Acute sensory ataxic neuropathy
New recruiting trial: Asan Multivessel Registry
A new clinical trial is recruiting patients for Acute sensory ataxic neuropathy
New recruiting trial: Asan Medical Center Myocardial Infarction Registry
A new clinical trial is recruiting patients for Acute sensory ataxic neuropathy
New recruiting trial: Asan Aorta and Peripheral Registry
A new clinical trial is recruiting patients for Acute sensory ataxic neuropathy
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Acute sensory ataxic neuropathy
What is Acute sensory ataxic neuropathy?
Acute sensory ataxic neuropathy (ASAN) is a rare acquired peripheral neuropathy characterized by the rapid onset of sensory ataxia — a loss of coordination caused by impaired proprioception (the body's sense of position and movement) rather than cerebellar dysfunction. It is classified within the spectrum of acute inflammatory demyelinating or axonal neuropathies and shares features with Guillain-Barré syndrome (GBS), specifically resembling an acute sensory variant. The condition predominantly affects the peripheral nervous system, targeting large-diameter sensory nerve fibers responsible for
How is Acute sensory ataxic neuropathy inherited?
Acute sensory ataxic neuropathy follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Acute sensory ataxic neuropathy typically begin?
Typical onset of Acute sensory ataxic neuropathy is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Acute sensory ataxic neuropathy?
Yes — 5 recruiting clinical trials are currently listed for Acute sensory ataxic neuropathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.